Clinical Trial Update: A Study of Decitabine Given Subcutaneously to Adults With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating subcutaneous decitabine in adults with low- or intermediate-1 risk myelodysplastic syndromes has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Decitabine (Decitabine)

Snippet

Sponsor: Eisai Inc. | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2013-09-18